Anti-tumor necrosis factor VNAR single domains reduce lethality and regulate underlying inflammatory response in a murine model of endotoxic shock

被引:25
|
作者
Bojalil, Rafael [1 ,2 ]
Teresa Mata-Gonzalez, Maria [3 ]
Sanchez-Munoz, Fausto [1 ]
Yee, Yepci [1 ]
Argueta, Ivan [1 ]
Bolanos, Lucia [1 ]
Manuel Amezcua-Guerra, Luis [1 ]
Amanda Camacho-Villegas, Tanya [4 ,5 ]
Sanchez-Castrejon, Edna [5 ]
Jakob Garcia-Ubbelohde, Walter [3 ]
Fedorovish Licea-Navarro, Alexei [5 ]
Marquez-Velasco, Ricardo [1 ,6 ]
Fernando Paniagua-Solis, Jorge [3 ]
机构
[1] Inst Nacl Cardiol Ignacio Chavez, Dept Immunol, Mexico City, DF, Mexico
[2] Univ Autonoma Metropolitana Xochimilco, Dept Hlth Care, Mexico City, DF, Mexico
[3] Labs Silanes, Mexico City 03100, DF, Mexico
[4] Univ Autonoma Baja California, Marine Sci Fac, Ensenada, Baja California, Mexico
[5] CICESE, Marine Biotechnol Dept, Ensenada, Baja California, Mexico
[6] Univ Valle Mexico, Dept Hlth Sci, Mexico City, DF, Mexico
关键词
Endotoxic shock; Sepsis; Anti-TNF; (V)NAR; Inflammation; NITRIC-OXIDE SYNTHASE; ANTIBODY FRAGMENTS; FACTOR-ALPHA; INTERLEUKIN-10; CONTROLS; MONOCLONAL-ANTIBODIES; ESCHERICHIA-COLI; INTERFERON-GAMMA; GENE-EXPRESSION; CECAL LIGATION; SEPSIS;
D O I
10.1186/1471-2172-14-17
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: In sepsis, tumor necrosis factor (TNF) is the key factor triggering respiratory burst, tissue injury and disseminated coagulation. Anti-TNF strategies based on monoclonal antibodies or F(ab')(2) fragments have been used in sepsis with contradictory results. Immunoglobulin new antigen receptors (IgNAR) are a unique subset of antibodies consisting of five constant ((C)NAR) and one variable domains ((V)NAR). (V)NAR domains are the smallest, naturally occurring, antibody-based immune recognition units, having potential use as therapy. Our aim was to explore the impact of an anti-TNF (V)NAR on survival in an experimental model of endotoxic shock. Also, mRNA expression and serum protein of several inflammatory molecules were measured. Results: Endotoxic shock was induced by lipopolysaccharide (LPS) in male Balb/c mice. Animals were treated with anti-TNF (V)NAR domains, F(ab')(2) antibody fragments, or saline solution 15 minutes before, 2 h and 24 h after lethal dose(100) (LD100) LPS administration. TNF blockade with either (V)NAR domains or F(ab')(2) fragments were associated with lower mortality (60% and 75%, respectively) compared to LD100. Challenge with LPS induced significant production of serum TNF and interleukins -10 and -6 at 3 h. After that, significant reduction of IL-6 at 24 h (vs 3 h) was shown only in the (V)NAR group. Nitrites level also increased in response to LPS. In liver, TNF and IL-10 mRNA expression showed a pro-inflammatory imbalance in response to LPS. Blocking TNF was associated with a shift towards an anti-inflammatory status; however, polarization was more pronounced in animals receiving F(ab')(2) fragments than in those with (V)NAR therapy. With regard to IL-6, gene expression was increased at 3 h in all groups. TNF blockade was associated with rapid and sustained suppression of IL-6 expression, even more evident in the (V)NAR group. Finally, expression of inducible-nitric oxide synthase (iNOS) increased in response to LPS at 3 h, but this was decreased at 24 h only in the anti-TNF (V)NAR group. Conclusions: Anti-TNF (V)NAR single domains improved survival in a murine model of endotoxic shock. Protection was associated with regulation in the TNF/IL-10 balance, attenuation of IL-6 and iNOS gene expression in the liver as well as decreased serum IL-6 concentration.
引用
收藏
页数:7
相关论文
共 9 条
  • [1] Anti-tumor necrosis factor VNAR single domains reduce lethality and regulate underlying inflammatory response in a murine model of endotoxic shock
    Rafael Bojalil
    María Teresa Mata-González
    Fausto Sánchez-Muñoz
    Yepci Yee
    Iván Argueta
    Lucía Bolaños
    Luis Manuel Amezcua-Guerra
    Tanya Amanda Camacho-Villegas
    Edna Sánchez-Castrejón
    Walter Jakob García-Ubbelohde
    Alexei Fedorovish Licea-Navarro
    Ricardo Márquez-Velasco
    Jorge Fernando Paniagua-Solís
    BMC Immunology, 14
  • [2] Anti-Tumor Necrosis Factor Therapies Reduce Serum Macrophage Inflammatory Protein-1α in Ankylosing Spondylitis
    Akbulut, Handan
    Koca, Suleyman S.
    Ozgen, Metin
    Isik, Ahmet
    JOURNAL OF RHEUMATOLOGY, 2010, 37 (05) : 1073 - 1074
  • [3] Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
    Marsal, Jan
    Barreiro-de Acosta, Manuel
    Blumenstein, Irina
    Cappello, Maria
    Bazin, Thomas
    Sebastian, Shaji
    FRONTIERS IN MEDICINE, 2022, 9
  • [4] Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease
    Matthew J Loza
    Rosemary Watt
    Frédéric Baribaud
    Elliot S Barnathan
    Stephen I Rennard
    Respiratory Research, 13
  • [5] Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease
    Loza, Matthew J.
    Watt, Rosemary
    Baribaud, Frederic
    Barnathan, Elliot S.
    Rennard, Stephen I.
    RESPIRATORY RESEARCH, 2012, 13
  • [6] Loss of Response to Anti-Tumor Necrosis Factor Alpha Therapy in Crohn's Disease Is Not Associated with Emergence of Novel Inflammatory Pathways
    Luther, Jay
    Gala, Manish
    Patel, Suraj J.
    Dave, Maneesh
    Borren, Nynke
    Xavier, Ramnik J.
    Ananthakrishnan, Ashwin N.
    DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (03) : 738 - 745
  • [7] Loss of Response to Anti-Tumor Necrosis Factor Alpha Therapy in Crohn’s Disease Is Not Associated with Emergence of Novel Inflammatory Pathways
    Jay Luther
    Manish Gala
    Suraj J. Patel
    Maneesh Dave
    Nynke Borren
    Ramnik J. Xavier
    Ashwin N. Ananthakrishnan
    Digestive Diseases and Sciences, 2018, 63 : 738 - 745
  • [8] Anti-tumor necrosis factor α: originators versus biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies
    Gioia, C.
    Diamanti, A. Picchianti
    Perricone, R.
    Chimenti, M. S.
    Afeltra, A.
    Navarini, L.
    Migliore, A.
    Massafra, U.
    Bruzzese, V.
    Scolieri, P.
    Meschini, C.
    Paroli, M.
    Caccavale, R.
    Scapato, P.
    Scrivo, R.
    Conti, F.
    Lagana, B.
    Di Franco, M.
    REUMATISMO, 2023, 75 (04) : 176 - 189
  • [9] Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease
    Ferreira, Filipa Bordalo
    Rafael, Maria Ana
    Coimbra, Lucia
    Boavida, Nazare
    Arrobas, Fernando
    Correia, Fabio Pereira
    Figueiredo, Luisa Martins
    Carvalho e Branco, Joana
    Lourenco, Luis Carvalho
    Santos, Liliana
    Oliveira, Ana Maria
    VACCINE, 2023, 41 (26) : 3862 - 3871